Skip to main content
All lobbying filings

ALSTON & BIRD LLP

Lobbying for BIOMERIEUX, INC. · Global in vitro diagnostics company.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Utah · House · Senate · $70,000.00 income · posted Apr 20, 2026

Official filing document

 Bills named in this filing 2
 Lobbying activity 5
Budget/Appropriations

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics.

Health Issues

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.

Medical/Disease Research/Clinical Labs

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.

Medicare/Medicaid

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

Trade (domestic/foreign)

Discussions regarding tariff proposals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem